Spitalul Universitar de Urgenţă Militar Central Dr Carol Davila Ringgold standard institution, Bucuresti, Romania.
Curr Med Res Opin. 2023 Jan;39(1):161-177. doi: 10.1080/03007995.2022.2124071. Epub 2022 Sep 22.
The therapeutic management of psychiatric disorders is currently confronted with a critical need to find new therapeutic interventions due to the high rates of non-responsivity or low responsivity in the key pathologies, e.g. schizophrenia spectrum disorders, alcohol use disorders, or major depressive disorder. The modulation of intestinal microbiota has been explored in various organic and psychiatric dysfunctions, with different degrees of success. However, this type of intervention may represent a helpful add-on at a conceptual level since it does not associate negative pharmacokinetics interactions, significant adverse events, or risk for non-adherence in the long term. Oral administration of pre-, pro-, or synbiotics, and especially the treatment with fecal microbiota transplantation (FMT), are methods still in their early research phase for patients with psychiatric disorders, therefore an exploration of data regarding the potential benefits and adverse events of FMT was considered necessary. In order to accomplish this purpose, the available results of research dedicated to each category of psychiatric disorders, starting with depressive and anxiety disorders, continuing with schizophrenia, substance use disorders, and finishing with disorders diagnosed during childhood, were presented in this paper. Seven clinical trials, 16 preclinical studies, three meta-analyses/systematic reviews, and six case reports, all of these representing ten distinct categories of psychiatric disorders or manifestations, have been reviewed. Mood disorders, anxiety disorders, and alcohol dependence have been the most extensively investigated clinical entities from the FMT efficacy and tolerability perspective, and reviewed data are generally promising. Based on the current status of research, FMT may be considered a helpful intervention in specific psychiatric pathologies. Still, this review showed that most of the information is derived from entirely preclinical studies. Therefore, clinical trials with sound methodology and more participants are needed to clarify FMT's benefits and risks in psychiatric disorders.
目前,由于精神疾病的关键病理(如精神分裂症谱系障碍、酒精使用障碍或重度抑郁症)的高无反应率或低反应率,精神障碍的治疗管理正面临寻找新治疗干预措施的迫切需求。肠道微生物群的调节已在各种有机和精神功能障碍中得到探索,取得了不同程度的成功。然而,这种干预类型可能代表了一种有益的辅助治疗方法,因为它不会产生负面的药代动力学相互作用、严重的不良事件或长期不依从的风险。口服前体、益生菌或合生元,特别是粪便微生物群移植(FMT)治疗,是针对精神障碍患者仍处于早期研究阶段的方法,因此有必要探索 FMT 的潜在益处和不良事件的数据。为了达到这个目的,本文介绍了从抑郁和焦虑障碍开始,然后是精神分裂症、物质使用障碍,最后是儿童期诊断的精神障碍,每一类精神障碍的研究结果。共审查了七个临床试验、十六个临床前研究、三个荟萃分析/系统综述和六个病例报告,所有这些都代表了十个不同类别的精神障碍或表现。从 FMT 疗效和耐受性的角度来看,心境障碍、焦虑障碍和酒精依赖是研究最多的临床实体,审查数据普遍有希望。基于目前的研究状况,FMT 可以被认为是一种对特定精神病理有帮助的干预措施。然而,本综述表明,大多数信息都来自于完全的临床前研究。因此,需要进行具有良好方法和更多参与者的临床试验,以明确 FMT 在精神障碍中的益处和风险。